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InvasionPreviou s cDNA microarrays indicated that CLDN1 (claudin-1) is an important gene for ovarian can- 
cer-init iating cell (OCIC) invasion and adhesion. Here, we show that the downregulation of miR-155 
in OCICs correlates with CLDN1 overexpression and the suppression of OCIC invasion. Luciferase 
assay s indicate that miR-155 targets CLDN1 mRNA on the 30 UTR. CLDN1 mRNA and claudin-1 protein 
expressi on were signiﬁcantly decreased in miR-155-OCICs. Proliferation assays and Transwell 
migration assays show that miR-155 signiﬁcantly suppresses the proliferative and invasive capacity 
of OCICs. Furthermore, miR-155 suppresses the growth of OCIC xenograft tumors. Thus, overexpres- 
sion of miR-155 may prevent tumorigenesis in human ovarian cancer through downregu lation of 
CLDN1.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. 1. Introduction 
MicroRNAs (miRNAs) are small RNA molecules (21–23 nt) that 
act as negative regulators of gene expression, either by blocking 
mRNA translation or through RNA interfere nce [1–3]. Previous 
studies revealed that the dysregulation of speciﬁc miRNAs is asso- 
ciated with certain types of cancer; these speciﬁc miRNAs act as 
either oncogenes or tumor suppressor s, depending on the target 
gene [1–6]. miR-155, for instance, is overexpressed in a variety of 
human cancers and immune system disorders, such as (a, b, c).
[4,5,7–14]. The expression of the primary-microR NA BIC 
(pri-miR-155) and mature miR-155 in three latency type III, Ep- 
stein-Barr virus (EBV)-positive Burkitt lymphoma cell lines and in 
all cases of primary post-transplan tation lymphop roliferative dis- 
orders suggests a possible role for EBV latency type III-speciﬁc pro- 
teins in the induction of BIC expression [4,5,7,15]; moreover , Jiang 
et al. discovered the way miR-155 promoting HK2 (encoding hexo- 
kinase-2) transcrip tion in breast cancer cells is achieved not only 
by the activation of signal transducer and activator of transcriptio n3, but also via repression of miR-143, which leads to releasing of 
inhibited C/EBP- b. They further reported that miR-155 controls 
glycolysis by regulating HK2 in breast cancer cells [16]. In addition, 
Kong et al. reported that miR-155 plays an important role in TGF- b/
Smad-ind uced epithelial –mesenchymal transition and in cell 
migration and invasion in breast cancer cells by targeting RhoA, 
suggestin g that miR-155 is a therapeuti c target for breast cancer 
interventi on [4]. As the clinical relevance of miRNAs to cancer 
has now been clariﬁed, and miR-155 overexpres sion has been re- 
ported in solid tumors of diverse origins (including breast, colon 
and lung), assays for measuring miR-155 expression may serve 
as tools for clinical diagnosis . [10].
Dysregul ation of tight junctions has often been associated with 
human diseases, including cancer [17]. Claudins (CLDNs) are a
family of integral membran e proteins central to the formation of 
tight junctions [17–20]. The expression of claudin-1 (CLDN-1), a
key constituent of tight junctions, is signiﬁcantly elevated in many 
cancer cells and causally associated with tumor growth and pro- 
gression [17–20]. Akasaka et al. reported that claudin-1 has an 
anti-apopto tic activity and is involved in regulatin g the expression 
and subcellular localization of b-catenin and E-cadher in in human 
breast cancer cells [21]; moreover, Suh et al. showed that CLDN1
has a causal role in epithelial–mesenchymal transition in human 
hepatoce llular carcinoma cells and that the c-Abl-Ras-Raf- 1- 
ERK1/2 signaling axis is critical for mediating CLDN1-induce d
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ported that claudin-1 overexpression in colon cancer is causally 
associated with tumor growth and progression; they concluded 
that the CLDN1 gene expression in human colon cancer cells is reg- 
ulated by homeodomai n transcrip tion factors CDX-1, CDX-2 and 
GATA-4. In addition, Krishnan et al. reported a novel post-tran- 
scriptional mechanism for regulating CLDN1 expression in colon 
cancer cells and further showed that histone deacetylase (HDAC)
inhibitors regulate claudin-1 expression in colon cancer cells by 
modulating mRNA stability [20].
We previously used cDNA microarray analysis to identify 
mRNAs that are differentiall y expressed in ovarian cancer-initiat- 
ing cells (OCICs; CD44 +/CD117+) and ovarian cancer cells (OCCs;
CD44/CD117) [22]. CLDN1 was one of the genes that were signif- 
icantly upregulated in OCICs [22]. However, the mechanisms 
underlying claudin-1 regulation during OCIC prolifera tion and 
invasion remain poorly understood. In this study, we discovered 
that miR-155 speciﬁcally targets on CLDN1, and that miR-155 over- 
expression inhibits OCIC proliferation and invasion, both in vitro 
and in vivo. Our results indicate that increased expression of 
endogenous mature miR-155 may inhibit human OCIC growth 
via reducing CLDN1 expression. Thus, CLDN1 may serve as an 
important new therapeutic target for human ovarian cancer. 
2. Materials and methods 
2.1. Isolation and in vitro expansion of CD44 +/CD117+ tumor cells by 
ﬂuorescence-activated cell sorting 
Ovarian tumors were collected from the inpatient clinic of 
Shanghai Changzheng Hospital (Shanghai, China) between May 
2012 and Dec 2012 (Supplement ary Table S1 ). CD44 +/CD117+ cell
subpopulation s were isolated from tumor samples, as previously 
described [6]. Brieﬂy, 4 lL of 10 mg/mL mouse anti-hum an 
CD117-FITC and rabbit anti-human CD44-PE (eBioscience) in a ﬁ-
nal volume of 1.0 mL were added to sedimented cells and incu- 
bated at 4 C in PBS for 30 min to block non-speciﬁc binding. 
Cells were then washed twice in PBS and CD44 +/CD117+ cells were 
isolated by ﬂow cytometry (BD FACSAria , BD Bioscienc e, CA, USA),
incubated at 10 C in PBS for 15 min and then washed twice in PBS. 
Isolated CD44 +/CD117+ OCICs were plated at 1000 cells/mL in 
DMEM:F12 medium (HyClone), supplem ented with 10 ng/mL of 
bFGF, 10 ng/mL of EGF, 5 lg/mL of insulin and 0.5% of BSA (all ob- 
tained from Sigma–Aldrich, St. Louis, USA) and grown at 37 C in a
humidiﬁed atmosph ere containing 5% CO 2. The resulting non- 
adherent spherical OCIC clusters were grown until passage 
4 before using for experiments .
2.2. Reporter vector construction 
A microRNA expression reporter plasmid was constructed as 
previously described [8,9]. A negative control plasmid was con- 
structed similarly, except that 11 nucleotides in the miR-155 seed 
sequence were mutated (TTAATGCT AAT was changed to TaAtTcCa-
AtT; mutations in lower case). OCICs were transfected with 0.3 lg
wild-type (WT) or mutant (Mut) miR-155 vector using Lipofect- 
amine 2000 (Invitrogen), according to the manufactur er’s protocol. 
2.3. RNA extraction and quantitative real-time PCR analysis 
Total RNA was isolated from each cell type using TRIzol Reagent 
(Invitrogen) according to the manufac turer’s protocol. RNA sam- 
ples were treated with DNase I (Sigma–Aldrich), quantiﬁed and re- 
verse-transcr ibed into cDNA using the ReverTra Ace- a First Strand 
cDNA Synthesis Kit (TOYOBO). Quantitative real-time PCR (qRT-PCR) was conducted using a RealPlex4 real-time PCR detection sys- 
tem (Eppendorf, Germany) with SYBR Green Realtime PCR Master 
MIX (TOYOBO). qRT-PCR ampliﬁcation was performed over 40 cy- 
cles of denaturation at 95 C for 15 s and annealed at 58 C for 45 s, 
and target cDNA was measured using the relative quantiﬁcation 
method. A comparative threshold cycle (Ct) was used to determine 
relative gene expression normalized to 18S rRNA. For each sample, 
Ct values were normalized using the formula: DCt = Ct_ge- 
nes  Ct_18S RNA. Relative expression levels were calculated using 
the formula: DDCt = DCt_all_gr oups  DCt_blankcon trol_group. 
Values applied to plot relative gene expression were calculated 
using the expression, 2DDCt. Primers used for cDNA ampliﬁcation
were as previousl y described [17–21].
2.4. Cell proliferation assay 
Cells were seeded at 2  103 per well in 96-well plates and cul- 
tured in DMEM supplemented with 10% fetal bovine serum (FBS) at 
37 C under 5% CO 2 until 85% conﬂuent. Methyl thiazolyl tetrazo- 
lium (MTT; Sigma Chemicals) reagent (5 mg/mL) was added at dif- 
ferent time points and incubated for a further 4 h. The reaction was 
terminat ed by adding 150 lL/well dimethyl sulfoxide (Sigma
Chemical s), cells were lysed for 15 min, and plates were gently 
shaken for 5 min. Absorbance at 490 nm was determined using a
Model 680 Microplate Reader (Bio-Rad).
2.5. Luciferase report assay 
Luciferas e report assays were done as previously described [8].
NIH-3T3 mouse embryonic ﬁbroblast cells were seeded at 3  104/
well in 48-well plates and co-transfected with 400 ng pRNAT- 
CMV 32 -m ir 155 -W T, pR NA T-C MV 32 -m ir 15 5- Mut or pR NA T- CMV 32 
(empty vector); 20 ng pGL3cm-CLDN 1-3UTR-WT or pGL3cm- 
CLDN1-3 UTR-Mut; and pRL-TK (Promega, Madison, USA) using 
Lipofectami ne 2000 according to the manufacturer’s protocol. 
Luciferas e activity was measure d after 48 h using the Dual-Lucife r- 
ase Reporter Assay System (Promega, Madison, USA).
2.6. Northern blotting 
Northern blotting was done as previously described [8,9]. For all 
cell treatment groups, 20 lg of high-quality total RNA was ana- 
lyzed on a 7.5 M urea, 12% PAA denaturing gel and transferred to 
a Hybond N+ nylon membrane (Amersham, Freiburg, Germany).
Membranes were cross-linked using ultraviolet light for 30 s at 
1200 mJ/cm 2 and hybridize d to the miR-155 antisense Starﬁre
probe, 50-CCCCTATCACG ATTAGCA TTAA-3 0 (IDT, Coralville, IA) for 
the detection of 22-nt miR-155 fragments, according to the manu- 
facturer’s instructions. After washing, membranes were exposed to 
Kodak XAR-5 ﬁlm for 20–40 h (Sigma–Aldrich Chemical). A human 
U6 snRNA probe (50-GCAGGGGC CATGCTAATCT TCTCTGTATCG -3 0)
was used as a positive control, with an exposure time of 15–
30 min. 
2.7. Western blotting 
Total protein extracts of each cell treatment group were re- 
solved by 12% SDS–PAGE and transferred onto polyviny lidene 
diﬂuoride (Millipore) membranes . After blocking, the membran es 
were washed four times for 15 min with Tris-buffered saline, con- 
taining 0.3% Tween-20 (TBST) at room temperature and then incu- 
bated with primary polyclonal antibodie s, as previously described 
[17–21]. After washing, membran es were incubate d at room tem- 
perature with secondary peroxidase-lin ked goat anti-rabb it IgG 
(1:1000 dilution; Santa Cruz Biotechn ology) for 1 h. Protein bands 
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Biotechnolo gy) and autoradio graphy. 
2.8. In vivo xenograft experiments 
Approximatel y 1  105 logarithmical ly growing OCICs were 
inoculated into BALB/c nude mice. Each experimental group con- 
sisted of four mice. After 100 days, the mice were sacriﬁced, fol- 
lowed by surgical excision of tumors [6]. The tumor was weighed 
and its volume was calculated accordin g to the formula: Tumor 
volume (mm3) = (ab2)/2, where a represents the longest axis 
(mm) and b the shortest axis (mm).
2.9. Statistical analysis 
Each experiment was performed as least three times; data were 
presented as mean ± S.E., where applicable, and differenc es were 
evaluated using Student’s t-tests. P values <0.05 were considered 
statistically signiﬁcant. 
3. Results 
3.1. Identiﬁcation of miR-155-bind ing sites in the CLDN1 30 UTR
The miRBase Target database [6,8] was used to analyze precur- 
sor miRNA (pre-miRNA) sequence s, mature miRNA sequences, 
chromosom al locations, length of miR-155, and potential target 
sites in the CLDN1 gene. A putative 7-nt miRNA target site was 
identiﬁed in the CLDN1 mRNA 30 untranslated region (30UTR) of 
several mammalian species (Fig. 1A). To examine whether CLDN1
expression was regulated by mature miR-155, a luciferase reporter 
containing a WT or Mut CLDN1 30 UTR miR-155- binding site, or an 
empty plasmid control, was co-transfected with miR-155 expres- 
sion vectors (WT-miR-155, Mut-miR-155 or empty vector control)
into NIH-3T3 cells. The activity of the luciferase reporter contain- 
ing WT CLDN1 30 UTR was signiﬁcantly inhibited following miR- 
155 co-transfecti on, while the activity of the reporter containing 
the mutated CLDN1 30 UTR site was unaffected by miR-155 co- 
transfection (Fig. 1). These results demonstrat ed that miR-155 tar- 
gets CLDN1 mRNA by speciﬁcally binding to the 30 UTR.3.2. Mature miR-155 downregulation in CD44 +/CD117+ OCICs
correlates with CLDN1 overexpressi on 
We previously used cDNA microarray analyses to identify 
mRNAs that were differentiall y expressed in OCICs and OCCs 
[22,23]; the expression of 21 mRNAs was decreased by more than 
2-fold in OCICs compared to OCCs, and the expression of 15 mRNAs 
was increased by more than 2-fold [22]. CLDN1 was one of the 
genes expresse d at a signiﬁcantly higher level in OCICs than in 
OCCs (Fig. 1) [22].
To conﬁrm this preliminary ﬁnding, OCICs were isolated and en- 
riched from ovarian tumor tissues and qRT-PCR was used to mea- 
sure endogenous CLDN1 expression in OCICs and OCCs. We found 
that CLDN1 mRNA expression was signiﬁcantly higher in OCICs 
than in OCCs (Fig. 1). Next, Northern blotting and miRNA-spec iﬁc
qRT-PCR (miR-qRT-PCR) was used to measure mature miR-155 
expression in OCICs and OCCs. MiR-155 hybridizatio n signals were 
weaker in OCIC extracts than in OCC extracts, thus revealing that 
miR-155 was downregulated in OCICs (Fig. 1). In addition, qRT- 
PCR analysis demonstrat ed that CLDN1 mRNA expression was re- 
duced following miR-155 transfection in OCICs, in contrast to cells 
transfected with Mut miR-155 (Fig. 1). Northern blot analysis also 
showed a strong miR-155 hybridiza tion signal in miR-155-tra ns- 
fected OCICs (Fig. 1). In order to detect the correlation between miR-155 and CLDN1, the Pearson correlation coefﬁcient test was 
used. After calculation, and the coefﬁcient (r) was determined 
(0.74846). These data indicated an inverse correlation between 
miR-155 and CLDN1 expression.
3.3. miR-155 suppresses OCIC proliferation, migration and invasion 
MTT assays indicated no signiﬁcant differenc es in the viability 
of OCICs transfected with WT or Mut miR-155 after 24 h. How- 
ever, WT miR-155 overexpression signiﬁcantly reduced OCIC 
prolifera tion after 48 h, 72 h and 96 h, compared to Mut miR- 
155-trans fected cells (Fig. 2), indicating that exogenous miR-155 
overexpres sion inhibits OCIC growth in vitro. In addition, miR- 
155 overexpression suppressed OCIC migration and invasion. The 
soft agar colony formation assay indicated that WT miR-155- trans- 
fected cells formed substanti ally fewer colonies when plated at low 
density than did Mut miR-155-trans fected cells (Fig. 2). Moreove r, 
the Transwell migration invasion assay showed the presence of 
signiﬁcantly fewer invading miR-155- transfected cells/well 
(12 ± 1) than Mut miR-155- transfected cells/well (25 ± 2). These 
results suggest that CLDN1 downregulation via miR-155 overex- 
pression signiﬁcantly attenuates OCIC invasion and migration. 
3.4. MiR-155 inhibition of CLDN1 downregulates cell adhesion proteins 
in OCICs 
qRT-PCR analysis and Western blotting were used to quantify 
the expression of cell adhesion-related proteins (E-cadherin,
b-catenin, MMP-2 and MMP-9) in WT and Mut miR-155-trans fected 
OCICs. We observed that levels of E-cadherin and b-catenin mRNAs
were signiﬁcantly higher in WT miR-155-tra nsfected cells than in 
Mut-miR- 155-transfecte d cells. However, the levels of MMP-2
and MMP-9 mRNAs were signiﬁcantly lower in WT miR-155- trans- 
fected cells than in other treatment groups (Fig. 2). Western blot- 
ting conﬁrmed that CLDN1 (0.34 ± 0.18 vs . 0.97 ± 0.32), MMP-2 
(0.14 ± 0.07 vs . 0.58 ± 0.18) and MMP-9 (0.20 ± 0.14 vs .
0.62 ± 0.16) protein expression was signiﬁcantly reduced in WT 
miR-155- transfected than in Mut miR-155-trans fected OCICs. 
However , b-catenin protein was signiﬁcantly overexpress ed in 
WT miR-155-tra nsfected (0.72 ± 0.25) than in Mut miR-155- trans- 
fected (0.26 ± 0.11) OCICs. These data indicated that exogenou s
miR-155 overexpression downregulates both endogen ous CLDN1
and cell adhesion-rel ated proteins in OCICs. 
3.5. MiR-155 overexpre ssion inhibits OCIC xenograft growth 
The effect of miR-155 overexpression on tumor growth in vivo 
was investigated by subcutan eous inoculation of WT or Mut miR- 
155-trans fected OCICs into nude mice. WT miR-155 overexpres- 
sion signiﬁcantly reduced tumor volume (Fig. 3A): all mice 
inoculated with Mut miR-155- transfected OCICs develope d tumors 
approximat ely 60 days after injection, whereas only one of the 
three mice inoculated with WT miR-155-tra nsfected OCICs had 
develope d a tumor by this time. Although both experime ntal 
groups eventually developed tumors, tumors formed by WT miR- 
155-trans fected cells grew more slowly than did those derived 
from Mut miR-155-trans fected cells (Fig. 3). Furthermore, when 
mice were sacriﬁced 100 days after injection , tumors obtained 
from the Mut miR-155-trans fected group were signiﬁcantly hea- 
vier than those of the WT miR-155-trans fected group (Fig. 3). Rep- 
resentati ve hematoxy lin and eosin-stained sections of all 
subcutan eous xenograft tumors derived from both WT and Mut 
miR-155- transfected OCICs were categorized as serous adenocarci -
nomas of moderate to poor different iation (Grade II/III). As tumor 
growth is determined by the balance of cell proliferation and 
Fig. 1. CLDN1 is a speciﬁc miR-155 target. (A) Typical secondary structure of the miR-155 pre-miRNAs, containing stem-loop and hairpin structures. The mature miR-155 
sequence was 100% homologous in all species examined. Complementarity between miR-155 and the human CLDN1 30 UTR target site is shown. (B) Luciferase reporter assays 
in NIH-3T3 mouse embryonic ﬁbroblast cells. Plasmid DNA containing the WT CLDN1 30 UTR miR-155-binding site (pGL3cm-CLDN1-3UTR-WT), mutated CLDN1 30 UTR MiR- 
155-binding site (pGL3cm-CLDN1-3UTR-Mut) or empty plasmid (pGL3cm) were co-transfected with an miR-155 expression vector (WT, Mut, or empty vector). Activity of the 
reporter containing the WT CLDN1 30 UTR was speciﬁcally inhibited by WT MiR-155 coexpression (⁄P < 0.05 and #P > 0.05; WT and Mut vs . PGL3cm transfection; n = 3). (C)
After ﬂuorescent-activated cell sorting, human CD44 +/CD117+ OCIC suspensions form small, non-adherent, non-symmetrical spheres under stem cell-selective conditions. 
Magniﬁcation: 200 . (D) qRT-PCR analysis of CLDN1 mRNA expression in OCICs and OCCs. Relative mRNA expression was normalized to 18S rRNA (⁄⁄P < 0.01 and #P > 0.05; 
OCICs vs. OCCs; n = 3). (E) qRT-PCR analysis of miR-155 expression in OCICs and OCCs (⁄⁄P < 0.01 and #P > 0.05; OCICs vs. OCCs; n = 3). (F) Northern blot of endogenous miR- 
155 expression in OCICs and OCCs derived from three clinical ovarian tumors (P1–P3). rRNA was used as loading control. (G) qRT-PCR analysis of CLDN1 mRNA expression in 
WT and Mut miR-155-transfected OCICs. Relative mRNA expression was normalized to that of 18S rRNA (⁄P < 0.05 and #P > 0.05; OCICs vs . OCCs; n = 3). (H) Northern blot 
analysis of miR-155 expression in WT and Mut miR-155-transfected OCICs. rRNA was used as loading control. 
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cell proliferation marker protein in tumor sections using immuno- 
histochemistr y. Tumors derived from Mut miR-155- transfected 
cells showed either positive or strongly positive Ki67 staining, 
whereas tumors formed from WT miR-155-tra nsfected cells exhib- 
ited only weak Ki67 immunoreactiv ity (Fig. 3). In contrast, more 
apoptotic cells were detected in tumors derived from the WT 
miR-155-tra nsfected cells. Thus, xenografts formed by WT miR- 
155-overexp ressing cells were smaller, with reduced proliferation 
and increased apoptosis than were those formed by Mut miR- 
155-overexp ressing cells. 
4. Discussion 
Current evidence suggests that the capacity for ovarian tumor 
formation and growth resides exclusively in a small proportio n of 
tumor cells, termed OCICs. OCICs were ﬁrst isolated from human 
ovarian tumor tissue based on the speciﬁc expression of CD44/ 
CD117 cell-surfa ce antigens [6,24]. The observati on that stem cells 
and OCICs share common deﬁning features of incomplete differen- 
tiation and a capacity for self-renewal and invasion have led to the 
cancer stem cell hypothesis, which states that the proliferation and 
invasion of a small subpopulation of cells is responsib le for tumor 
growth [6,24]. OCICs are known with an enhanced tumor-initiatin g
and self-renewa l capacity, a low degree of different iation, ahigh invasive growth pattern, a partial recreatio n of cellular 
heteroge neity of the parental tumor, and a generally more resistant 
behavior than other cancer cells to conventional anticance r thera- 
pies [6,24]. These properties link OCICs to tumor recurren ce and 
distant metastasis; therefore, it is essential to elucidate their un- 
ique signaling and regulatory mechanism s in order to design spe- 
ciﬁc therapies targeting ovarian cancer-initiati ng cells. However, 
the mechanisms controlling OCIC proliferation and invasion are 
complicated and still poorly understo od. To date, several reports 
have indicated that CLDN1 protein is overexpressed in some cancer 
cells [17–21]. CLDN1 regulates cell–cell interactions , cell adhesion 
and migration [17–21]. However, a common function of CLDN1 in
both OCCs and OCICs has not been reported. In this study, we 
proved for the ﬁrst time that OCICs overexpress the CLDN1 protein
and that miR-155 is downregulated in these cells. Moreover, 
CLDN1 overexpression in OCICs results in a low degree of differen- 
tiation and a high rate of invasion. MiR-155 overexpress ion in 
OCICs led to growth inhibition in vitro. Moreover, soft agar colony 
formatio n and Transwell migration invasion assays showed that 
the cell invasion was signiﬁcantly reduced in WT miR-155- trans- 
fected cells, compared with Mut miR-155-tra nsfected cells. In 
addition, qRT-PCR and Western blotting analyses showed that E- 
cadherin and b-catenin expression was signiﬁcantly higher in WT 
miR-155- transfected OCICs than that in Mut miR-155-trans fected 
cells, but MMP-2 and MMP-9 mRNA levels were signiﬁcantly lower 
Fig. 2. Exogenous miR-155 overexpression inhibits the proliferation and invasion capacity of OCICs. (A) MTT assays of WT and Mut miR-155-transfected OCICs (⁄P < 0.05; WT 
vs . Mut miR-155; n = 3). (B) Transwell migration invasion assays of WT and Mut miR-155-transfected OCICs (⁄P < 0.05 and cells; #P > 0.05; WT vs . Mut miR-155; n = 3). (C)
Soft agar colony formation of WT and Mut miR-155-transfected OCICs after low-density plating (⁄P < 0.05 and #P > 0.05; WT vs . Mut miR-155; n = 3). (D) qRT-PCR analysis of 
cell adhesion-related mRNAs (E-cadherin, b-catenin, MMP-2 and MMP-9) in WT and Mut miR-155-transfected OCICs, normalized to 18S rRNA (⁄⁄P < 0.01, ⁄P < 0.05 and 
#P > 0.05; WT vs . Mut miR; n = 3). (E) Western blot analysis and quantiﬁcation of CLDN1, b-catenin, MMP-2 and MMP-9 protein expression in WT and Mut miR-155- 
transfected OCICs. GAPDH was used as a loading control (⁄⁄P < 0.01, ⁄P < 0.05 and #P > 0.05; WT vs . Mut miR-155; n = 3).
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groups. In addition, xenograft experime nts indicated that WT 
miR-155 expression in OCICs suppresses tumor growth and Fig. 3. Mir-155 inhibits the growth of OCICs in vivo. WT and Mut miR-155-transfected
excised xenograft tumors. (B) WT miR-155 expression delays tumor growth. All mice in 
injection; tumors formed by the miR-155-WT-transfected cells grew more slowly (⁄P
(⁄P < 0.05; WT vs . Mut miR-155; n = 4). (D) Hematoxylin and eosin staining of tumor
transfected group revealing the cellular heterogeneity. Original magniﬁcation: 100 . R
from miR-155-WT-transfected group or miR-155-Mut-transfected OCICs spheroid cel
(Grade II/III), similar to the parental primary patient tumors. (E) Immunohistochemi
staining in the tumors formed from and miR-155-Mut-transfected OCICs (b) positive 
cells. Magniﬁcation: 100 .invasion in vivo. In conclusio n, we report that miR-155 targets 
on CLDN1 and reduces CD44 +/CD117+ ovarian cancer-initiating cell 
prolifera tion and invasion both in vitro and in vivo.  human OCICs were subcutaneously inoculated into SCID mice. (A) Images of the 
the Mut miR-155-transfected group developed tumors approximately 60 days after 
< 0.05 and #P > 0.05; WT vs . Mut miR-155; n = 3). (C) Tumor weight at 100 days 
 tissues formed in the (a) miR-155-Mut-transfected group and (b) miR-155-WT- 
epresentative H&E staining sections of all subcutaneous xenograft tumors derived 
ls were categorized as serous adenocarcinomas of moderate/poor differentiation 
cal staining of the cell proliferation marker Ki67 indicating (a) strongly positive 
or strongly positive staining in the tumors formed from miR-155-WT-transfected 
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